Your browser doesn't support javascript.
loading
A Multidisciplinary Hyper-Modeling Scheme in Personalized In Silico Oncology: Coupling Cell Kinetics with Metabolism, Signaling Networks, and Biomechanics as Plug-In Component Models of a Cancer Digital Twin.
Kolokotroni, Eleni; Abler, Daniel; Ghosh, Alokendra; Tzamali, Eleftheria; Grogan, James; Georgiadi, Eleni; Büchler, Philippe; Radhakrishnan, Ravi; Byrne, Helen; Sakkalis, Vangelis; Nikiforaki, Katerina; Karatzanis, Ioannis; McFarlane, Nigel J B; Kaba, Djibril; Dong, Feng; Bohle, Rainer M; Meese, Eckart; Graf, Norbert; Stamatakos, Georgios.
  • Kolokotroni E; In Silico Oncology and In Silico Medicine Group, Institute of Communication and Computer Systems, School of Electrical and Computer Engineering, National Technical University of Athens, 157 80 Zografos, Greece.
  • Abler D; Department of Oncology, Geneva University Hospitals and University of Geneva, 1205 Geneva, Switzerland.
  • Ghosh A; Department of Oncology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Tzamali E; Department of Chemical and Biomolecular Engineering, Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Grogan J; Institute of Computer Science, Foundation for Research and Technology-Hellas, 70013 Heraklion, Greece.
  • Georgiadi E; Irish Centre for High End Computing, University of Galway, H91 TK33 Galway, Ireland.
  • Büchler P; In Silico Oncology and In Silico Medicine Group, Institute of Communication and Computer Systems, School of Electrical and Computer Engineering, National Technical University of Athens, 157 80 Zografos, Greece.
  • Radhakrishnan R; Biomedical Engineering Department, University of West Attica, 12243 Egaleo, Greece.
  • Byrne H; ARTORG Center, University of Bern, 3010 Bern, Switzerland.
  • Sakkalis V; Department of Chemical and Biomolecular Engineering, Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Nikiforaki K; Mathematical Institute, University of Oxford, Oxford OX1 2JD, UK.
  • Karatzanis I; Institute of Computer Science, Foundation for Research and Technology-Hellas, 70013 Heraklion, Greece.
  • McFarlane NJB; Institute of Computer Science, Foundation for Research and Technology-Hellas, 70013 Heraklion, Greece.
  • Kaba D; Institute of Computer Science, Foundation for Research and Technology-Hellas, 70013 Heraklion, Greece.
  • Dong F; The Cambridge Crystallographic Data Centre, Cambridge CB2 1EZ, UK.
  • Bohle RM; Department of Computer Science and Technology, University of Bedfordshire, Luton LU1 3JU, UK.
  • Meese E; Department of Computer & Information Sciences, University of Strathclyde, Glasgow G1 1XH, UK.
  • Graf N; Department of Pathology, Saarland University, 66421 Homburg, Germany.
  • Stamatakos G; Department of Human Genetics, Saarland University, 66421 Homburg, Germany.
J Pers Med ; 14(5)2024 Apr 29.
Article en En | MEDLINE | ID: mdl-38793058
ABSTRACT
The massive amount of human biological, imaging, and clinical data produced by multiple and diverse sources necessitates integrative modeling approaches able to summarize all this information into answers to specific clinical questions. In this paper, we present a hypermodeling scheme able to combine models of diverse cancer aspects regardless of their underlying method or scale. Describing tissue-scale cancer cell proliferation, biomechanical tumor growth, nutrient transport, genomic-scale aberrant cancer cell metabolism, and cell-signaling pathways that regulate the cellular response to therapy, the hypermodel integrates mutation, miRNA expression, imaging, and clinical data. The constituting hypomodels, as well as their orchestration and links, are described. Two specific cancer types, Wilms tumor (nephroblastoma) and non-small cell lung cancer, are addressed as proof-of-concept study cases. Personalized simulations of the actual anatomy of a patient have been conducted. The hypermodel has also been applied to predict tumor control after radiotherapy and the relationship between tumor proliferative activity and response to neoadjuvant chemotherapy. Our innovative hypermodel holds promise as a digital twin-based clinical decision support system and as the core of future in silico trial platforms, although additional retrospective adaptation and validation are necessary.
Palabras clave